Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

BACKGROUND: In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Hyun Kyeong, Byun, Han Geul, Caprioli, Flavio, Fumery, Mathurin, Peyrin-Biroulet, Laurent, Sreedhar, Subramanian, Potter, James, Jang, Minyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636776/
https://www.ncbi.nlm.nih.gov/pubmed/36333704
http://dx.doi.org/10.1186/s12913-022-08683-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636776/
https://www.ncbi.nlm.nih.gov/pubmed/36333704
http://dx.doi.org/10.1186/s12913-022-08683-y

Ejemplares similares